Latest Updates

Pediatric Minimally Invasive Pyeloplasty

Pasquale Casale, MD, Julia Beth Finkelstein, MD
    • Pediatric robotic pyeloplasty is safe and effective, with comparative studies showing similar success and complication rates between minimally invasive and open pyeloplasty.
    • Anderson-Hynes dismembered pyeloplasty is the standard approach for repair, but robotic approaches can be tailored to the specific case when complex patient anatomy is encountered.
    • Several benefits of robotic pyeloplasty are intimated; previously unrecognized advantages include human capital gain, indirect benefits from shortened hospitalizations, and parental satisfaction. 

Stress Fractures And The Reproductive System In The Female Athlete

Irfan M Asif, MD, Kimberly Harmon, MD, Mallory Shasteen, MD
    • Due to the radiation exposure involved with oblique radiography and CT, the recommended imaging modalities when spondylolysis is suspected include initial two-view radiography followed by MRI.
    • Surgery for spondylolysis is recommended only when bilateral spondylolysis is present and has progressed to significant spondylolisthesis.
    • Female athletes should have 1,500 mg/day of calcium and maintenance of vitamin D levels at 32 to 50 ng/mL, which may generally occur with 800 IU of vitamin D/day.
    • Female athletes should have baseline dual-energy x-ray absorptiometry if they have one or more “high-risk” triad risk factors or two or more “moderate-risk” triad risk factors. 

Clinical Management of Feeding and Eating Disorders

Anne Marie O’Melia , MD, Patricia Westmoreland, MD
    • Lisdexamfetamine for the treatment of binge eating disorder
    • Novel deep brain stimulation, repetitive transcranial magnetic stimulation, and transcranial direct current stimulation
    • Novel treatments for severe and enduring forms of anorexia nervosa

Autoimmune Hepatitis/Overlap  Syndromes

Albert J Czaja, MD
    • Autoimmune hepatitis may have laboratory and histological features that resemble PBC or PSC, and PBC and PSC may have features of autoimmune hepatitis. These mixed clinical phenotypes constitute the overlap syndromes, and they may have a variable response to the conventional therapies used for each unmixed classical disease.
    • Clinical judgment and expert interpretation of liver tissue are the principal bases for diagnosing the overlap syndromes, and incompatible manifestations of cholestasis (disproportionate serum AP and GGT elevations, destructive cholangitis or ductopenia in liver tissue) or liver inflammation (disproportionate serum AST and ALT elevations, interface hepatitis, and dense lymphoplasmacytic infiltration in liver tissue) are hallmarks of the diagnosis.
    • Autoimmune hepatitis with cholestatic features that are unassociated with AMA or an abnormal cholangiography suggests the possibility of an overlap syndrome with AMA-negative PBC or small duct PSC.
    • Therapy is guided by the predominant component of the overlap syndrome and consists mainly of prednisone or prednisolone, azathioprine, and low dose UDCA (13 to 15 mg/kg daily) in combination. Management strategies can be tailored to the individual patient and adjusted according to the response. High dose UDCA (28 to 30 mg/kg daily) should be avoided.
    • Management of a nonresponse to the frontline regimen consists mainly of modifying the original treatment by adding corticosteroids or low dose UDCA if not present initially or considering the empirical use of mycophenolate mofetil as a substitute for azathioprine or a calcineurin inhibitor as a substitute for corticosteroids. Salvage drug therapies have had a limited clinical experience. Liver transplantation should be considered for features of liver failure.

Autoimmune Hepatitis/Overlap  Syndromes

Albert J Czaja, MD
    • Autoimmune hepatitis may have laboratory and histological features that resemble PBC or PSC, and PBC and PSC may have features of autoimmune hepatitis. These mixed clinical phenotypes constitute the overlap syndromes, and they may have a variable response to the conventional therapies used for each unmixed classical disease.
    • Clinical judgment and expert interpretation of liver tissue are the principal bases for diagnosing the overlap syndromes, and incompatible manifestations of cholestasis (disproportionate serum AP and GGT elevations, destructive cholangitis or ductopenia in liver tissue) or liver inflammation (disproportionate serum AST and ALT elevations, interface hepatitis, and dense lymphoplasmacytic infiltration in liver tissue) are hallmarks of the diagnosis.
    • Autoimmune hepatitis with cholestatic features that are unassociated with AMA or an abnormal cholangiography suggests the possibility of an overlap syndrome with AMA-negative PBC or small duct PSC.
    • Therapy is guided by the predominant component of the overlap syndrome and consists mainly of prednisone or prednisolone, azathioprine, and low dose UDCA (13 to 15 mg/kg daily) in combination. Management strategies can be tailored to the individual patient and adjusted according to the response. High dose UDCA (28 to 30 mg/kg daily) should be avoided.
    • Management of a nonresponse to the frontline regimen consists mainly of modifying the original treatment by adding corticosteroids or low dose UDCA if not present initially or considering the empirical use of mycophenolate mofetil as a substitute for azathioprine or a calcineurin inhibitor as a substitute for corticosteroids. Salvage drug therapies have had a limited clinical experience. Liver transplantation should be considered for features of liver failure.

Viral Hepatitis C: Treatment

Raymond T. Chung, MD, Jacinta A Holmes, MBBS, PhD, Anna Lidofsky, BS, Jay Luther, MD, Stephanie M Rutledge, MBBCh BAO MRCPI
    • Recent advances in treatment of chronic HCV to include interferon-free direct-acting antiviral agent regimens
    • Latest treatment recommendations, including special populations
    • Issues surrounding treatment-emergent resistance-associated variants 

Human Trafficking 3: Intervention And Therapy

Wendy Macias-Konstantopoulos, MD, MPH
    • As of May 2017, the commercial sexual exploitation or trafficking of a child under the age of 18 is considered a form of child sexual abuse under the law and would require reporting in all 50 states, the District of Columbia, and the US territories.
    • If the ED physician has a concern for an active infection, testing and treatment are indicated, but in the absence of an active STI, clinicians can forego testing and counsel patients regarding presumptive treatment based on updated guidelines for antiretroviral postexposure prophylaxis following a potential sexual, injection drug use, or other nonoccupational exposure to HIV.

Urologic Infections

Nisa S Atigapramoj, MD, Tatyana Vayngortin, MD
    • UTI evaluation and management varies by age; rapid diagnosis and treatment prevents complications; infants may present solely with fever
    • Most common uropathogen is Escherichia coli (85%). Other pathogens include gram-negative bacteria and more rarely gram-positive bacteria
    • Antibiotic treatment should be based on local antibiograms plus individual patient risk factors and history
    • Indications for inpatient admission include: age under 2 months, sepsis, vomiting/inability to tolerate oral antibiotics, infection with a multidrug-resistant organism, immunocompromised state, a complicated social situation, or risk of no follow up
    • Risk factors for UTI in infants include age <12 months, uncircumcised males, temperature >39°C. Risk factors in adults include pregnancy, sexual activity, immunosuppression, urologic abnormalities or obstruction, long-term urinary catheter, neurogenic bladder, urinary incontinence
« Previous | Next »
Updates per yearSpecialty updatesNumber of sections